Scout | Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

This opportunity is no longer accepting applications.

grant

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

This grant opportunity supports the early development of new small-molecule and biologic drugs aimed at preventing, slowing, or treating Alzheimer's disease. Funding is available for activities including medicinal chemistry, pharmacokinetics, toxicology studies, animal model efficacy, biomarker development, drug formulation, GMP chemical synthesis, IND-enabling studies, and Phase I clinical tr…

Source

Agency: National Institutes of Health

Sub-agency: National Institute on Aging

Program: SBIR

Award

Award Ceiling: $1.5M

Funding Amount: $1.5M

Dates

Opportunity Released: June 25, 2024

Open for Submission: June 25, 2024

Submission Deadline: November 5, 2027

Application Window Closes: November 5, 2027

Keywords

Alzheimer's disease

drug development

pre-clinical

Phase I clinical trial

small-molecule

biologic drug

biomarkers

pharmacokinetics

Good Manufacturing Practices

Investigational New Drug.

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers